[{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CV0601","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ GSK"},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"CV0701","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ GSK"},{"orgOrder":0,"company":"CordenPharma","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"TAK-919","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CordenPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CordenPharma \/ Moderna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"CordenPharma \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Biotest","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Trimodulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biotest \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biotest \/ Inapplicable"},{"orgOrder":0,"company":"Apogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Asunercept","moa":"CD95","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apogenix \/ Inapplicable"},{"orgOrder":0,"company":"Apogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Asunercept","moa":"CD95","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apogenix \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BI 764198","moa":"TRPC6","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"Biocure Technology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"zapnometinib","moa":"MEK receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atriva Therapeutics \/ Biocure Technology","highestDevelopmentStatusID":"8","companyTruncated":"Atriva Therapeutics \/ Biocure Technology"},{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"zapnometinib","moa":"MEK receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"zapnometinib","moa":"MEK receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"zapnometinib","moa":"MEK receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Swiss TPH","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2023","type":"Partnership","leadProduct":"Emodepside","moa":"Gqalpha protein\/Phospholipase-Cbeta","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Swiss TPH","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Swiss TPH"},{"orgOrder":0,"company":"AiCuris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pritelivir","moa":"Viral Helicase-primase complex","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AiCuris \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AiCuris \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"GSK4382276A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ Biogen"},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"GSK4382276A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ GSK"},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"GSK4382276A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ GSK"},{"orgOrder":0,"company":"Berlin Cures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Rovunaptabin","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Berlin Cures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Berlin Cures \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Berlin Cures \/ Inapplicable"},{"orgOrder":0,"company":"Berlin Cures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Rovunaptabin","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Berlin Cures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Berlin Cures \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Berlin Cures \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Flu mRNA (GSK4382276A) is a intramuscularly administered mRNA-based multivalent seasonal influenza vaccine, which is being evaluated for the treatment of seasonal influenza.

                          Product Name : GSK4382276A

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          May 28, 2024

                          Lead Product(s) : GSK4382276A

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : GSK

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : CV0701 is a biovalent vaccine candidate, which encodes the spike protein of the omicron BA.4-5 variant and it is under phase 2 clinical development for the treatment of Covid-19 infection.

                          Product Name : CV0701

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          May 01, 2024

                          Lead Product(s) : CV0701

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : GSK

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : BC 007 (rovunaptabin) is a novel therapeutic candidate using DNA-based aptamers to target and neutralize functional autoantibodies against G-protein coupled receptors for Long COVID.

                          Product Name : BC 007

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          April 23, 2024

                          Lead Product(s) : Rovunaptabin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Flu mRNA (GSK4382276A) is a intramuscularly administered mRNA-based multivalent seasonal influenza vaccine, which is being evaluated for the treatment of seasonal influenza.

                          Product Name : GSK4382276A

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          April 04, 2024

                          Lead Product(s) : GSK4382276A

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : GSK

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : BC 007 is a DNA-based aptamer designed to specifically target and neutralize functional autoantibodies (fAABs) directed against G-protein coupled receptors. It is being evaluated for Long Covid.

                          Product Name : BC 007

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          April 03, 2024

                          Lead Product(s) : Rovunaptabin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Through a licensing agreement, GSK will acquire full rights from Curevac of Flu mRNA (GSK4382276) to develop, manufacture, and commercialize globally mRNA candidate vaccines for influenza.

                          Product Name : GSK4382276A

                          Product Type : Vaccine

                          Upfront Cash : $429.2 million

                          March 07, 2024

                          Lead Product(s) : GSK4382276A

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Biogen

                          Deal Size : $1,556.0 million

                          Deal Type : Licensing Agreement

                          blank

                          07

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Through the acquisition, Atriva aims to develop novel, highly efficacious and safe therapies for the treatment of severe diseases caused by RNA-viruses, including ATR-002 (zapnometinib), a first-in-class, host-targeting agent that aims to inhibit viral r...

                          Product Name : ATR-002

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 18, 2023

                          Lead Product(s) : zapnometinib

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Biocure Technology

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          08

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The partnership aims to jointly develop emodepside, an anthelmintic substance that is effective against several gastrointestinal nematodes in domestic animals, in the clinical development for treating humans infected with soil-transmitted helminths.

                          Product Name : BAY 44-4400

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          July 20, 2023

                          Lead Product(s) : Emodepside

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Swiss TPH

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          09

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The monovalent candidate, CV0601, encodes the spike protein of the omicron BA.4-5 variant and is being developed in collaboration with GSK

                          Product Name : CV0601

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          January 08, 2023

                          Lead Product(s) : CV0601

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : GSK

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : RESPIRE1 is an international, multi-center Phase II clinical trial in 220 adult patients with moderate to severe COVID-19, requiring hospitalization, but not requiring ICU admission or ventilator support at the time of screening or randomization.

                          Product Name : ATR-002

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 13, 2021

                          Lead Product(s) : zapnometinib

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank